Entrada Therapeutics, INC

Entrada Therapeutics announced that its stockholders approved amendments to its 2021 Stock Option and Incentive Plan and 2021 Employee Stock Purchase Plan at the 2026 Annual Meeting.

Entrada Therapeutics announced positive topline results from Cohort 1 of its Phase 1/2 ELEVATE-44-201 study for Duchenne Muscular Dystrophy, alongside Q1 2026 financial results and an updated cash runway.

Entrada Therapeutics announced its fourth quarter and full year 2025 financial results, alongside significant clinical progress in its Duchenne muscular dystrophy (DMD) and inherited retinal disease programs.

Entrada Therapeutics reported significant progress across its RNA-based therapeutic portfolio for neuromuscular and ocular diseases, including Duchenne muscular dystrophy programs and a new candidate for Usher syndrome, while maintaining a cash runway into Q3 2027.

Entrada Therapeutics reported Q3 2025 financial results, highlighted significant progress in its Duchenne muscular dystrophy clinical programs, and extended its cash runway into Q3 2027.

Entrada Therapeutics announced its Q2 2025 financial results, highlighted significant clinical advancements in its Duchenne muscular dystrophy programs, and expanded its leadership team.

Entrada Therapeutics announced its first-quarter 2026 financial results, highlighting progress in its Duchenne Muscular Dystrophy (DMD) programs and its collaboration with Vertex Pharmaceuticals.

Entrada Therapeutics reported a significant net loss for the nine months ended September 30, 2025, driven by decreased collaboration revenue and increased R&D expenses, while advancing its Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) clinical programs.

Entrada Therapeutics, a clinical-stage biopharmaceutical company, reported a significant net loss in Q2 2025 due to a sharp decline in collaboration revenue and increased research and development expenses, despite advancing its Duchenne muscular dystrophy pipeline.

Entrada Therapeutics reports a net loss for Q1 2025, focuses on DMD clinical programs, and advances partnered candidate VX-670 with Vertex.

Entrada Therapeutics announced positive preliminary Phase 1 clinical trial data for ENTR-601-44 and plans to submit regulatory applications for Phase 2 trials.

Entrada Therapeutics reports a significant increase in collaboration revenue and net income for the second quarter of 2024, primarily driven by its partnership with Vertex Pharmaceuticals.

Entrada Therapeutics reports a significant net loss for 2025 despite advancing multiple clinical programs for Duchenne muscular dystrophy and inherited retinal diseases, with cash runway into Q3 2027.

Entrada Therapeutics' 10-K filing highlights advancements in its Duchenne muscular dystrophy (DMD) programs, including the lifting of a clinical hold on ENTR-601-44 and planned clinical trial initiations.

Entrada Therapeutics finalizes a significant lease agreement for its headquarters while progressing its pipeline, including a collaboration with Vertex Pharmaceuticals.

5AM Ventures V, L.P. and 5 others reported changes in beneficial ownership of Entrada Therapeutics, Inc. common stock on July 30, 2026.

Kush Parmar, a Director and 10% owner of Entrada Therapeutics, Inc., sold 116,474 shares of common stock on July 30, 2026.

Director Kush Parmar was granted 19,000 stock options in Entrada Therapeutics, Inc. as part of standard equity compensation.

Director Peter S. Kim was granted 19,000 stock options in Entrada Therapeutics, Inc. as part of standard equity compensation.

Entrada Therapeutics director Gina Chapman was granted 19,000 stock options as part of standard equity compensation.

Entrada Therapeutics director Maha Radhakrishnan was granted 19,000 stock options as part of standard equity compensation.

Entrada Therapeutics announces its 2026 Annual Meeting of Stockholders, scheduled for June 10, 2026, to elect directors and ratify auditor appointment.

Entrada Therapeutics, Inc. announced the expansion of its Board of Directors and the appointment of Dr. Maha Radhakrishnan, a seasoned biopharmaceutical executive, effective June 1, 2025.

Entrada Therapeutics, Inc. will hold its 2025 Annual Meeting online on June 11, 2025, with voting open until June 10, 2025.

Entrada Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 11, 2025, to elect directors and ratify the appointment of its accounting firm.

Entrada Therapeutics will hold its 2024 Annual Meeting online on June 13, 2024, featuring proposals for director election, auditor ratification, and liability limitation for officers.

Entrada Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 13, 2024, to vote on director election, auditor ratification, and an amendment to limit officer liability.

5AM Ventures and affiliates disclosed selling 200,000 Entrada shares and updated beneficial ownership stakes ranging from 2.9% to 10.8%.

TCG Crossover Fund I, L.P., TCG Crossover GP I, LLC, and Chen Yu have jointly reported a 5.0% beneficial ownership stake in Entrada Therapeutics, Inc.

T. Rowe Price Associates, Inc. has filed an amendment to its Schedule 13G, disclosing a 0.9% beneficial ownership stake in Entrada Therapeutics Inc.

T. Rowe Price Associates, Inc. has disclosed a 6.8% beneficial ownership stake in Entrada Therapeutics Inc. common stock, held for passive investment purposes.

Janus Henderson Group plc has filed an Amendment No. 2 to Schedule 13G, reporting a 4.0% beneficial ownership stake in Entrada Therapeutics, Inc. as of June 30, 2025.

Janus Henderson Group plc and its affiliates have filed an amended Schedule 13G, disclosing a passive beneficial ownership of 5.6% in Entrada Therapeutics, Inc.'s common stock as of March 31, 2025.

Roche Finance Ltd and its parent, Roche Holding Ltd, have reaffirmed their substantial passive ownership in Entrada Therapeutics, Inc., holding 6.9% of the common stock as of December 31, 2024.